Medicine
Immunopathogenesis of Long COVID and Potential Therapeutic Targets
Quick fact
In long COVID, the immune system can remain in a heightened inflammatory state for months after the acute infection clears, causing symptoms like fatigue and brain fog even when the virus is no longer detectable.
Why this is interesting
Millions who survived COVID-19 still feel unwell months later. What if the virus isn't gone, but has left the immune system stuck in a harmful loop?
Read the full explanation
Understanding Immunopathogenesis of Long COVID and Potential Therapeutic Targets
Think of the immune system as a home security system. In long COVID, the alarm doesn't turn off. After a SARS-CoV-2 infection, some people's immune cells stay persistently activated, producing inflammatory molecules that damage tissues and cause symptoms. This can happen because viral fragments linger in the body, continuously triggering the alarm, or because the immune system becomes dysregulated, unable to distinguish friend from foe, leading to autoimmunity. Meanwhile, other immune cells, like T-cells, become exhausted—like a guard who has worked too many shifts and no longer responds effectively. This dysfunction explains the wide range of long COVID symptoms, from fatigue to cognitive impairments.
A deeper explanation
The mechanism of long COVID involves several interacting pathways. First, viral persistence: SARS-CoV-2 RNA and proteins can be detected in tissues months after infection, likely in reservoirs like the gut or lymph nodes, providing ongoing antigenic stimulation. This drives chronic inflammation, with elevated levels of cytokines like IL-6 and TNF-α. Second, immune dysregulation: the persistent antigenic exposure causes T-cell exhaustion, characterized by increased expression of inhibitory receptors like PD-1, leading to reduced effector function and failure to clear the virus. This allows continued viral presence and inflammation. Third, autoimmunity: molecular mimicry or bystander activation can lead to the production of autoantibodies against host tissues, perpetuating tissue damage. These mechanisms converge to produce the clinical picture of long COVID, and they define potential therapeutic targets. Therapies aim to clear the viral reservoir with antivirals like Paxlovid, modulate the immune response with anti-inflammatory agents such as baricitinib, or restore exhausted T-cell function using checkpoint inhibitors. Understanding this interplay is crucial for developing effective treatments and reducing the global burden of the disease.